Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure

Monika Sadlonova1,2,3*, Thomas Meyer1,3, Lutz Binder3,4, Rolf Wachter3,5,6, Frank Edelmann5,7,8,9 and Christoph Herrmann-Lingen1,3

Abstract

Background: Galectin-3 promotes the proliferation of neural progenitor cells and is engaged in cell-cell adhesion, cell-matrix interactions, and macrophage activation. In addition, in patients with heart failure this carbohydrate-binding protein is a known prognostic marker for cardiovascular mortality. However, its association with psychological variables has not been investigated so far.

Methods: Using data from the multicenter, observational Diast-CHF (Diagnostic Trial on Prevalence and Clinical Course of Diastolic Dysfunction and Heart Failure) trial, we studied in participants with cardiovascular risk factors (n = 1260, age 66.7 ± 8.0 years, males 51%, left ventricular ejection fraction 60.0 ± 8.1%) the relationship between serum concentrations of galectin-3 and anxiety. Galectin-3 levels were measured by means of a sandwich enzyme-linked immunosorbent assay, and anxiety was assessed using the Hospital Anxiety and Depression Scale (HADS).

Results: In univariate analysis, there was a weak but significant inverse correlation between galectin-3 and HADS anxiety (ρ = −0.076; p = 0.008). Linear regression models adjusted for sex, age, body-mass index, estimated glomerular filtration rate, left ventricular ejection fraction, 6-min walking distance, the 36-item Short-Form Health Survey (SF-36) subscale physical functioning, and known biomarkers for heart failure confirmed that serum galectin-3 significantly and independently predicted self-rated anxiety (B = -2.413; 95%CI = -2.413 – -4.422; p = 0.019).

Conclusion: In patients with cardiovascular risk factors, serum concentrations of galectin-3 showed an inverse association with anxiety, which was independent of both the severity of physical impairment and established risk factors for the progression of heart failure.

Keywords: Galectin-3, Anxiety, Cardiovascular risk factors

* Correspondence: monika.sadlonova@med.uni-goettingen.de

1Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center, Göttingen, Germany
2Department of Thoracic and Cardiovascular Surgery, University of Göttingen Medical Center, Göttingen, Germany
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
In patients with cardiac diseases, the impact of anxiety on prognosis has been controversially discussed in the literature. While only two observational studies reported a protective effect of anxiety on mortality in patients with coronary heart disease, numerous studies demonstrated that anxiety disorders are associated with increased mortality and worse prognosis [1–8]. In patients with heart disease, several parameters of neuroendocrine activation and inflammation have been found increased and some of these markers, such as natriuretic peptides or C-terminal pro-arginine vasopressin (CT-proAVP), have been proposed to elicit anxiolytic effects [9–16]. Galectin-3 has been introduced as another prognostic biomarker for increased mortality risk in heart failure [17–24]. This 35 kDa protein belongs to the family of β-galactoside-binding lectins with a carboxyl-terminal lectin domain connected to an amino-terminal non-lectin segment including several repeats of a proline/tyrosine/glycine-rich motif [25, 26]. It is expressed in inflammatory processes by mast cells and macrophages, where it regulates cell-cell adhesion, cell-matrix interactions, proliferation, angiogenesis, and induction of pre-mRNA splicing [27, 28]. The secretion of galectin-3 activates fibroblasts and myofibroblasts to secrete procollagen into the extracellular matrix as a component in the cardiac remodeling process [29–31]. However, possible associations of galectin-3 with emotional well-being in general, and anxiety in particular, are unclear.

Sartim et al. reported that galectin-3 knockout mice had increased compulsive-like behavior and, in addition, showed higher immobility times in the forced swim test and tail suspension test, suggesting an impaired stress-coping behavior [32]. Notably, Stajic and colleagues showed that galectin-3-deficient mice displayed anxiogenic effects in mature untreated animals compared to wild-type animals, and this was accompanied by reduced interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) gene expression and protein content in the hippocampus [33]. However, in humans, specific associations of galectin-3 with anxiety have not been studied so far. To address the question whether serum levels of galectin-3 are associated with anxiety, we used data from the population-based, multicenter Diagnostic Trial on Prevalence and Clinical Course of Diastolic Dysfunction and Heart Failure (Diast-CHF) study and looked for associations of the serum galectin-3 measurements with self-assessed anxiety in subjects presenting with a cardiovascular risk profile.

Methods
Study design
The baseline assessment of the prospective, multicenter Diast-CHF trial was conducted in the years 2004 to 2006 as part of the nationwide German Competence Network Heart Failure, which aimed at assessing the prevalence of diastolic left ventricular dysfunction in medical outpatients treated by primary care physicians [34]. The participants in this observational study were 1727 outpatients aged 50–85 years with cardiovascular risk factors and/or manifest heart failure. An additional control group of 208 healthy volunteers was excluded from the present analysis, as were 49 participants with known atrial fibrillation and 136 subjects lacking echocardiographic parameters for diastolic dysfunction. Due to the lack of galectin-3 measurements and incomplete data on psychometric assessment, another 282 participants were excluded. In the end, the study population analyzed in this work comprised 1260 participants with complete data. Medical outpatients were eligible as study participants if they had at least one cardiovascular risk factor for the development of diastolic heart failure, such as diabetes mellitus, coronary heart disease, hypertension, sleep apnea, history of myocardial infarction, or manifest heart failure. Exclusion criteria were insufficient understanding of the German language, unwillingness to give informed consent and/or unavailability for logistic reasons. All participants received routine physical examination and a detailed echocardiogram for the assessment of systolic and diastolic function, including the American Society of Echocardiography (ASE) grade and ejection fraction (LVEF). Before being included in the study, all patients gave their written informed consent. The study protocol was approved by all local institutional ethics committees and complies with the Declaration of Helsinki.
Laboratory measurements

From each study participant, venous blood samples were drawn and collected in tubes from the antecubital vein after 15 min of rest in a prone position. Heparinized and EDTA samples were immediately obtained by centrifugation, and supernatants were subsequently stored at –80°C until they were analyzed in a specialized laboratory. The measurements of galectin-3 were performed using a sandwich-ELISA (enzyme-linked immunosorbent assay) from BG Medicine, Waltham, MA/USA. This immunoassay used a rat and a mouse monoclonal antibody raised against a mouse galectin-3 protein [38, 39]. The measuring and linearity range of galectin-3 was given as 1.4–94.8 ng/mL for clinical specimens. The total coefficient of variation was 12% at a concentration of 6.1 ng/mL, and 7.7% at 20.7 ng/mL. The 90th, 95th and 97.5th percentiles in an apparently healthy population were 17.6 ng/mL, 20.3 ng/mL and 22.1 ng/mL, respectively [39]. In healthy subjects aged 55 years or more, the 95% range interval was from 3.8 to 21 ng/mL [38]. In patients with decompensated heart failure, the concentration of galectin-3 is between 4 to 75 ng/mL with a cutoff value of 22.1 ng/mL.

Since we previously observed an inverse association of natriuretic peptides and CT-proAVP with anxiety in the same cohort, we additionally controlled for natriuretic peptides and CT-proAVP in the present analysis [14, 16]. N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured with a non-competitive electroluminescence immunoassay (Elecsys, Roche Diagnostics, Mannheim, Germany) using a monoclonal biotinylated NT-proBNP antibody directed against amino acids 1–21 and a secondary monoclonal antibody conjugated to a ruthenium complex binding to amino acids 39–50 [40, 41]. Mid-regional MR-proANP was determined in EDTA plasma using an immunoluminometric assay (SERI STRA from B.R.A.H.M.S) with two polyclonal affinity-purified sheep antibodies directed against different peptide fragments of proANP [42]. The biomarker CT-proAVP was measured with a commercially available chemiluminescence sandwich assay (B.R.A.H.M.S., Hennigsdorf, Germany) using antibodies against the two peptides PATV17 and PLAY17 [43, 44].

Statistical analysis

Demographic and clinical data are presented as means and standard deviations or frequencies and percentages, while plasma levels of galectin-3 and other biomarkers are given as medians and 25th and 75th percentiles. The biomarkers were logarithmically transformed prior to further analysis in order to approach normal distribution, which was tested using the Shapiro-Wilk test. In general, laboratory variables were not distributed normally even after log transformation. In view of this lack of normal distribution, we used Spearman’s correlation for examining the bivariate relationship between galectin-3 and HADS anxiety. A linear regression model was computed with HADS anxiety as dependent variable adjusted for sex, age, body-mass index (BMI), estimated glomerular filtration rate (eGFR), left ventricular ejection fraction (LVEF), American Society of Echocardiography (ASE) grade of diastolic dysfunction, 6-min walking distance, and SF-36 physical functioning, while plasma galectin-3 was additionally entered as an independent variable (model 1). These variables were selected based on our previous publication in order to maintain the results comparable [16]. In a second model, plasma NT-proBNP, MR-proANP and CT-proAVP were entered as additional confounders. All analyses were performed using SPSS software, version 25 (SPSS Inc., Chicago, IL, USA). A p value of <0.05 was considered statistically significant.

Results

Approximately half of the study population were men (51%), and the mean age of the participants was 66.7 ± 8.0 years (Table 1). Due to the inclusion criteria, the majority of all patients (82.7%) were suffering from echocardiographically documented diastolic dysfunction, as judged by an American Society of Echocardiography grade of ≥1. Less than 7% of all participants were suffering from heart failure symptoms with New York Heart Association (NYHA) class II or higher. The most frequent cardiovascular risk factor was arterial hypertension, which was observed in 1118 participants (88.7%). In the total study cohort, the mean HADS anxiety score was 5.1 ± 3.7. The median galectin-3 concentration was 11.7 ng/mL (25th and 75th percentile: 9.9 and 14.1 ng/mL), and the median plasma level of NT-proBNP was 101.4 pg/mL (25th and 75th percentile: 52.5 pg/mL and 193.1 pg/mL). For MR-proANP, the median concentration was 91.9 pmol/L (25th and 75th percentile: 64.4 pmol/L and 135.1 pmol/L), whereas for CT-proAVP this was 4.1 pmol/L (25th and 75th percentile, 2.6 and 7.6 pmol/L). The mean HADS score gradually decreased from the first and lowest quartile of serum galectin-3 (5.75) over the second quartile (5.09) to the third quartile (4.81), and was stable in the fourth and highest quartile (4.83). This difference between the quartiles was statistically significant (p = 0.005). A detailed characterization of the study population is presented in Table 1.

In Spearman’s correlation analysis, we found weak but significant positive correlations of galectin-3 with NT-proBNP (rho = 0.065, p = 0.003), MR-proANP (rho = 0.068, p = 0.012) and age (rho = 0.078, p = 0.005). There was also a significant negative correlation of galectin-3 with HADS anxiety (rho = -0.076, p = 0.008) and eGFR (rho = -0.063,
respectively (Fig. 1). There was no statistically significant correlation between galectin-3 and high sensitive C-reactive-protein (\(\rho = -0.019, p = 0.513\)).

In a linear regression model adjusted for gender, age, BMI, eGFR, LVEF, ASE grade, 6-min walking test, and SF-36 physical functioning, we found that log-transformed galectin-3 concentrations independently predicted HADS anxiety (\(B = -2.493, 95\% CI = -4.354–-0.632, p = 0.009\)) (Table 2, model 1). The coefficient of determination (\(R^2\)) for this model was 0.115. A similar result was obtained for serum galectin-3, when the model was adjusted exclusively for age and sex (\(p = 0.009\)).

Finally, we tested whether the inverse and significant association between galectin-3 and HADS anxiety remained stable, when additionally NT-proBNP, MR-proANP and CT-proAVP were included as confounders in the model. Data showed that, also in this model, galectin-3 was a significant and independent predictor

### Table 1: Baseline characteristics of the study cohort

|                          | n     | Total study cohort | Patients with galectin-3 below the median split | Patients with galectin-3 above the median split | \(P\) value |
|--------------------------|-------|--------------------|--------------------------------------------------|--------------------------------------------------|------------|
| **Clinical data**        |       |                    |                                                  |                                                  |            |
| Age (years)              | 1260  | 66.7 ± 8.0         | 66.2                                             | 67.2                                             | 0.028      |
| Married (%)              | 1207  | 66.9               | 66.1                                             | 67.7                                             | 0.563      |
| Body-mass index (kg/m\(^2\)) | 1255  | 29.2 ± 4.9         | 29.3 ± 4.8                                       | 29.2 ± 5.0                                       | 0.661      |
| Heart rate (beats/min)   | 1253  | 70.2 ± 12.0        | 70.6 ± 12.5                                      | 69.7 ± 11.6                                      | 0.157      |
| Systolic blood pressure (mmHg) | 1257  | 149.4 ± 21.3       | 149.1 ± 20.9                                     | 149.7 ± 21.8                                     | 0.650      |
| Diastolic blood pressure (mmHg) | 1257  | 84.1 ± 11.9        | 84.4 ± 11.8                                      | 83.9 ± 12.0                                      | 0.408      |
| 6-min walking distance (m) | 1160  | 506.9 ± 111.5      | 509.1 ± 113.0                                    | 504.7 ± 110.1                                    | 0.502      |
| Hypertension (%)         | 1260  | 88.7               | 89.0                                             | 88.3                                             | 0.672      |
| Hyperlipidemia (%)       | 1260  | 45.1               | 44.8                                             | 45.3                                             | 0.871      |
| Diabetes mellitus (%)    | 1260  | 28.3               | 29.3                                             | 27.4                                             | 0.470      |
| Coronary heart disease (%) | 1260  | 21.0               | 19.6                                             | 22.3                                             | 0.224      |
| Previous myocardial infarction (%) | 1260  | 10.3               | 8.6                                              | 12.0                                             | 0.044      |
| Sleep apnea (%)          | 1260  | 6.5                | 7.5                                              | 5.5                                              | 0.166      |
| Current smokers (%)      | 1259  | 11.2               | 11.6                                             | 10.8                                             | 0.884      |
| LVEF (%)                 | 1249  | 60.0 ± 8.1         | 59.9 ± 8.1                                       | 60.2 ± 8.1                                       | 0.537      |
| ASE grade                | 1173  | 1.07 ± 0.65        | 1.1 ± 0.66                                       | 1.03 ± 0.63                                      | 0.001      |
| **Neurohumoral parameters** |       |                    |                                                  |                                                  |            |
| Galectin-3 (ng/mL)       | 1260  | 11.7 a (9.9;14.1)b  | 9.9 a (8.7;10.7)b                                | 14.1 a (12.8;16.3)b                               | < 0.001    |
| CT-proAVP (pmol/L)       | 1220  | 4.1 a (2.6;7.6)b    | 4.1 a (2.6;7.6)b                                | 4.2 a (2.6;7.6)b                                 | 0.757      |
| NT-proBNP (pg/mL)        | 1160  | 101.4 a (52.5;193.1)b  | 78.6 a (43.3;151.9)b                            | 125.6 a (65.1;256.1)b                            | < 0.001    |
| MR-proANP (pmol/L)       | 1219  | 91.9 a (64.4;135.1)b | 87.5 a (61.4;128.8)b                             | 96.3 a (67.0;143.4)b                             | 0.228      |
| **Psychometric variables** |       |                    |                                                  |                                                  |            |
| HADS Anxiety             | 1230  | 5.1 ± 3.7          | 5.4 ± 3.9                                       | 4.8 ± 3.5                                        | 0.005      |
| SF-36 Physical functioning | 1237  | 72.0 ± 25.0        | 72.9 ± 25.1                                      | 71.0 ± 24.9                                      | 0.173      |
| **Medication use**       |       |                    |                                                  |                                                  |            |
| ACE inhibitor (%)         | 1239  | 45.0               | 44.2                                             | 45.8                                             | 0.570      |
| AT1 receptor antagonist (%) | 1239  | 19.0               | 20.3                                             | 17.8                                             | 0.256      |
| Beta-blocker (%)          | 1239  | 50.0               | 54.0                                             | 46.0                                             | 0.005      |
| Diuretics (%)            | 1239  | 49.7               | 51.4                                             | 48.1                                             | 0.245      |
| Statins (%)              | 1239  | 31.7               | 31.7                                             | 31.7                                             | 0.993      |
| ASS (%)                  | 1239  | 35.6               | 36.7                                             | 34.5                                             | 0.399      |
| Insulin and/or oral antidiabetics (%) | 1239  | 21.1               | 20.7                                             | 21.6                                             | 0.671      |

Results are presented as means and standard deviations, percentages or frequencies, a median, b25th and 75th percentile. **ASE** American Society of Echocardiography, **CT-proAVP** C-terminal pro-arginine vasopressin, **HADS** anxiety subscale of the Hospital Anxiety and Depression Scale, **LVEF** left ventricular ejection fraction, **MR-proANP** mid-regional pro-atrial natriuretic peptide, **NT-proBNP** N-terminal pro-brain natriuretic peptide, **SD** standard deviation
for anxiety (B = -2.413, 95%CI = -4.422—-0.404, p = 0.019) (Table 2, model 2). However, the natriuretic peptides MR-proANP and NT-proBNP concentration failed to predict self-assessed anxiety. In contrast, the CT-proAVP concentration was inversely and significantly associated with anxiety (B = -0.913, 95%CI = -1.776—-0.050, p = 0.038) (Table 2, model 2).

Discussion

The main finding of this post-hoc analysis from the Diast-CHF study is that, in a cohort of patients with cardiovascular risk factors, the plasma concentration of galectin-3 is inversely correlated with self-assessed anxiety. This relationship between galectin-3 and HADS anxiety was weak but remained stable when, in a multivariate model, clinical variables indicative of physical impairment were added as putative confounders. Our data demonstrate that, independently of natriuretic peptides and the biomarker CT-proAVP, higher levels of circulating galectin-3 predict less anxiety, suggesting that the β-galactoside-binding protein galectin-3 may modulate neuronal pathways engaged in the regulation of anxiety. Our observation extends previous findings from animal and clinical studies suggesting that galectin-3-mediated pathways are implicated in a variety of processes associated with myocardial fibrosis, tissue repair, inflammation, myofibroblast proliferation, and ventricular remodeling. However, our cross-sectional data do not prove a causal effect of galectin-3 on anxiety. Higher anxiety might also lead to suppressed production and/or release of galectin-3 or both could depend on an unknown third factor not identified in our analyses.

Psychological stressors, especially those that produce a state of fear, commonly lead to relevant anxiety, which concurrently explains why stress and anxiety share overlapping physiological reactions. The anti-inflammatory effects of cortisol usually associated with increased stress levels and anxiety may have an overall suppressive effect on the synthesis and subsequent release of galectin-3 in the circulation [45]. In line, we observed in our study population that decreased circulating galectin-3 concentrations are linked to higher levels of anxiety, which may in turn have resulted from a chronically elevated psychological stress level. Thus, our main finding of an inverse relationship between self-rated anxiety and galectin-3 secretion into the circulation may not be completely unexpected.

In an important study in mice, it was showed that a single episode of immobilization stress reduces galectin-3 expression in the liver, spleen and in macrophages. These animal experiments suggest that galectin-3 is involved in the overall regulation of physiological responses to psychological stress [25]. Untreated mice lacking galectin-3 expression showed anxiogenic
behaviors compared to wild-type animals, and this was associated with lower brain-derived neurotrophic factor (BDNF) gene expression and immunoreactivity in hippocampal tissue (predominantly in the CA1 region) [33]. Interestingly, hippocampal gene expression of the GABA-A receptor subunits 2 and 5 was attenuated in the transgenic mice.

It has been shown that galectin-3 overexpression in hypoxic and nutrient-deprived microenvironments promotes a cell survival adaptive program under stressing conditions [46]. In contrast, knockdown of galectin-3 expression led to reduced NF-κB promoter activity and secretion of interleukin-8 and attenuated inflammatory response in the peritoneal cavity, further confirming its activation in inflammatory tissue microenvironments [47]. Complexes with galectin-3 have been described as ligands activating Toll-like receptors and mediating NF-κB signal transduction [25]. Oligomers of galectin-3 interact with a variety of cell surface glycoproteins and serve as scaffolds for the spatial organization of signaling receptors. Galectin-3 is a mediator of microglia responses in injured brain regions promoting cell proliferation and cell survival [48].

However, it is unknown whether or not galectin-3 expressed in the brain has any functions in mediating anxious behavior in humans. Beside its prognostic value for heart failure patients [20, 49, 50], our data from the Diast-CHF study suggest an unknown mechanism of galectin-3 in the regulation of anxiety also in humans. Thus, this galactoside-binding lectin may be added to the growing list of peptides functioning as prognostic biomarkers of heart failure (NT-proBNP, NT-proANP, MR-proANP, CT-ET-1, CT-proAVP, and MR-proadrenomedullin) that, in addition, negatively associate with anxiety [13–16, 51, 52].

The present post-hoc analysis has important methodological limitations, which result mainly from the observational and cross-sectional design of the study. No causal inferences can be made from our findings, as longitudinal data were not available. Moreover, we noted that the described effects are generally small and there are no direct implications for routine clinical care from

Table 2 Results from multivariate regression models in the Diast-CHF study group with HADS anxiety as the dependent variable

| Model 1: Total model p < 0.001, adjusted R² = 0.115, F = 15.051 |
|-----------------|-----------------|-----------------|-----------------|
|                | β               | 95% confidence interval | P value |
| Galectin-3     | -2.493          | -4.354;0.632       | 0.009  |
| Gender         | 0.605           | 0.128;1.082        | 0.013  |
| Age            | -0.054          | -0.091;0.018       | 0.004  |
| BMI            | 0.055           | -0.114;0.004       | 0.066  |
| eGFR           | 0.008           | -0.004;0.020       | 0.214  |
| LVEF           | 0.021           | -0.009;0.050       | 0.173  |
| ASE grade      | 0.136           | -0.219;0.490       | 0.453  |
| 6-min walking distance | 0.002         | -0.001;0.004       | 0.127  |
| SF-36 physical functioning | -0.057       | -0.068;0.045       | < 0.001 |

Model 2: Total model p < 0.001, adjusted R² = 0.108, F = 9.483

|                | β               | 95% confidence interval | P value |
| Galectin-3     | -2.413          | -4.422;0.404           | 0.019  |
| Gender         | 0.249           | -0.323;0.821           | 0.394  |
| Age            | -0.053          | -0.094;0.013           | 0.010  |
| BMI            | -0.034          | -0.101;0.033           | 0.318  |
| eGFR           | -0.002          | -0.016;0.012           | 0.809  |
| LVEF           | 0.007           | -0.025;0.039           | 0.669  |
| ASE grade      | 0.200           | -0.189;0.589           | 0.314  |
| 6-min walking distance | 0.002         | -0.001;0.004           | 0.287  |
| SF-36 physical functioning | -0.056       | -0.069;0.043           | < 0.001 |
| CT-proAVP      | -0.913          | -1.776;0.050           | 0.038  |
| NT-proBNP      | -0.286          | -1.212;0.640           | 0.545  |
| MR-proANP      | -0.843          | -2.665;0.979           | 0.364  |

Results from multivariate linear regression models with HADS anxiety scores as dependent variable and plasma galectin-3 as independent variable adjusted for gender, age, BMI body-mass index, eGFR estimated glomerular filtration rate, LVEF left ventricular ejection fraction, ASE grade American Society of Echocardiography, 6-min walking distance, SF-36 physical functioning and, optionally, CT-proAVP, and natriuretic peptides NT-proBNP and MR-proANP.
Conclusion

In patients with cardiovascular risk factors, serum galectin-3 is linked to anxiety and this relationship is independent of physical impairment and serum concentrations of natriuretic peptides. The association between galectin-3 and HADS anxiety is weak and remains stable in multivariate models adjusted to clinically relevant confounders. Galectin-3 is added to the growing list of prognostic biomarkers of heart failure negatively associated with anxiety.

Authors’ contributions

MS conducted the statistical analysis and drafted the manuscript. TM contributed to data interpretation. LB collected important data. FE and RW jointly supervised the design of this study. CHL supervised the project and contributed to writing and editing. All authors critically reviewed and approved the final version of the manuscript.

Funding

The study was supported by a grant from the German Federal Ministry of Education and Research.

Availability of data and materials

Data from participants who agreed to the public distribution of data are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

The study protocol was approved by the ethics committee of the Medical Faculty of the University of Göttingen. Informed consent was obtained from each participant.

Consent for publication

Consent for publication was obtained from each participant.

Competing interests

CHL reports that he is receiving royalties from Hogrefe Huber Publishers for the German version of the HADS. During the last 3 years, he has received lecture honoraria from Servier, Heel, and Novartis. LB received reagents for the determination of NT-proBNP from Roche Diagnostics. All other authors report no conflicts of interest.

Author details

1Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center, Göttingen, Germany. 2Department of Thoracic and Cardiovascular Surgery, University of Göttingen Medical Center, Göttingen, Germany. 3German Center for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany. 4Institute for Clinical Chemistry, University of Göttingen Medical Center, Göttingen, Germany. 5Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany. 6Department of Cardiology, University of Leipzig Medical Center, Leipzig, Germany. 7Department of Internal Medicine and Cardiology, Charte University Medicine, Campus Virchow Klinikum, Berlin, Germany. 8German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany. 9Berlin Institute of Health (BIH), Berlin, Germany.

Received: 14 April 2020 Accepted: 9 June 2020

Published online: 02 October 2020

References

1. Meyer T, Buss U, Herrmann-Lingen C. Role of cardiac disease severity in the predictive value of anxiety for all-cause mortality. Psychosom Med. 2010;72: 9–15.
2. Meyer T, Hussein S, Lange HW, Herrmann-Lingen C. Anxiety is associated with a reduction in both mortality and major adverse cardiovascular events five years after coronary stenting. Eur J Prev Cardiol. 2015;22:75–82.
3. Frasure-Smith N, Lespérance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry. 2008;65:62–71.
4. Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA. Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease: The Heart and Soul Study. Arch Gen Psychiatry. 2010;67:750–8.
5. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol. 2010;56:38–46.
6. Watkins LL, Koch GG, Sherwood A, Blumenthal JA, Davidson JR, O’Connor C, Sketch MH. Association of anxiety and depression with all-cause mortality in individuals with coronary heart disease. J Am Heart Assoc. 2013;2:e00068.
7. Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77:439–48.
8. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170:1015–25.
9. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:1534–9. Erratum in: J Am Coll Cardiol. 1989;14:812.
10. Hall C, Rouleau JL, Moyé L, de Champlain J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89:1934–42.
11. Aflaghan U, Dahlström U, Rehfeld JF, Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011;305:2086–95.
12. Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mickel M, Hogan C, Wu AH, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail. 2011;4:613–20.
13. Herrmann-Lingen C, Binder L, Klinge M, Sander J, Schenker W, Beyermann B, von Lewinski D, Peske B. High plasma levels of N-terminal pro-atrial natriuretic peptide associated with low anxiety in severe heart failure. Psychosom Med. 2003;65:517–22.
14. Meyer T, Herrmann-Lingen C, Chavanon ML, Nolte K, Pasedach CA, Binder L, Peske B, Basenfuss G, Wachtler R, Edelmann F. Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational Diast-CHF study. Clin Res Cardiol. 2015;104:74–81.
15. Fangauf SV, Herbeck Belnap B, Meyer T, Albus C, Binder L, Deter HC, Ladwig KH, Michal M, Ronel J, Rothenberger A, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoendocrinology. 2018;96:188–94.
16. Sadlonova M, Meyer T, Binder L, Edelmann F, Wachtler R, Herrmann-Lingen C. Higher plasma levels of CT-proAVP are linked to less anxiety in men but not women with cardiovascular risk factors: Results from the observational Diast-CHF study. Psychoendocrinology. 2019;101:722–7.
17. Edelmann F, Holzendorf V, Wachtler R, Nolte K, Schmidt AG, Kraigher-Kainer E, Duvinage A, Unkelbach I, Dungen HD, Tschöpe C, et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2015;17:214–23.
18. Ho JE, Liu C, Lyass A, Coucheney P, Pencina MJ, Larson MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2011;60:1249–56.
19. van Kimmendonk RR, Januzi JJ, Jr, Ellison PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, et al. Utility of amino-
20. Lok DJ, van der Meer P, de la Porte PWBA, Lipsic E, van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol. 2010;99:233–8.

21. Lok DJ, Lok S, de la Porte PWBA, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102:103–10.

22. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:36–32.

23. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:680–9.

24. van Bark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, de Boer RA, Asselbergs FW, Wajon EM CJ, Onsel JG, Boersma E, et al. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. J Am Heart Assoc. 2017;6:e003700.

25. Dumić J, Barišić K, Fišglov M, Lauc G. Galectin-3 decreases in mice exposed to immobilization stress. Stress. 2003;6:241–6.

26. de Boer RA, Voors AA, Muntenendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811–7.

27. Kızellak A, Lipirńska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9:305–28.

28. Sundblad V, Croci DO, Rabinovich GA. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. Histol Histopathol. 2011;26:2479–90.

29. de Filippi CR, Christenson RH. Activated macrophages in failure-prone hypertrophied hearts and Galectin-3 in human and murine heart failure. Eur J Heart Fail. 2011;13:857–64.

30. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12:36–32.

31. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. J Am Heart Assoc. 2017;6:e003700.

32. de Boer RA, Voors AA, Muntenendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811–7.

33. Kızellak A, Lipirńska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett. 2004;9:305–28.

34. Sundblad V, Croci DO, Rabinovich GA. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. Histol Histopathol. 2011;26:2479–90.

35. Herrmann-Lingen C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale – Deutsche Version (HADS-D). 3rd ed. Bern: Hans Huber Publishing Company; 2011.

36. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.

37. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.

38. Carlsson M, Borgia A, Gallusser A, Huber E, Krueger K, Rülling W, Schenk J. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl. 1999;290:177–81.

39. Mueller T, Gegenhuber A, Poezt W, Halmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunomass assay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem. 2003;49:976–9.